Proteases represent common targets in combating infectious diseases, including COVID-19.
The 3-chymotrypsin-like protease (3CLpro) is a validated molecular target for COVID-19 …

ABSTRACT Introduction Nirmatrelvir/ritonavir (Paxlovid®) represent an oral antiviral therapy
approved for the treatment of COVID-19. Extensive in vitro and in vivo studies have reported …

How do we best use Paxlovid and other covid antivirals? | The BMJ Skip to main content
Intended for healthcare professionals Access provided by Google Indexer Subscribe My …

The scientific and medical community faced an unprecedented global health hazard that led
to nearly 7 million deaths attributable to the rapid spread of severe acute respiratory …

Background The advantages and disadvantages of casirivimab-imdevimab for coronavirus
disease 2019 are not well understood. We conducted a systematic review and meta …

ABSTRACT OBJECTIVES To establish a population pharmacokinetics (PopPK) model of
nirmatrelvir in Chinese COVID-19 patients and provide reference for refining the dosing …

The SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) virus and the
resulting COVID-19 pandemic have had devastating and lasting impact on the global …

Фавипиравир, разработанный японскими исследователями в качестве средства
терапии гриппа и других РНК-вирусных инфекций, в 2020-2022 годах стал массово …

Motivated by the ambiguity of operational case definitions for long COVID and the impact of
the lack of a common causal language on long COVID research, in early 2023 we began …

Актуальность исследования. В последние десятилетия эпидемические вспышки и
пандемии, вызываемыми возбудителями вновь появляющихся инфекционных …